Logo Image
|Articles|December 1, 2011

Bio-tests for Schizophrenia And Depression

Listen
0:00 / 0:00

Key Takeaways

The race to patent bio-tests for schizophrenia and depression: some say this initiative is destined to fail.

Recent articles by Arline Kaplan and Hagop Asiskal, MD, highlight the race to patent bio-tests for schizophrenia and depression. Dr Max Fink continues the discussion in his commentary; he contends the DSM divisions serve patients and doctors poorly. Tell us what you think.
 

Related Content

Latest CME

Southern California Psychiatry Conference
In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!
(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more